• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BECTON, DICKINSON & CO. (SPARKS) BOTTLE TB AURAMINE M 250ML; SYSTEM, BLOOD CULTURING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BECTON, DICKINSON & CO. (SPARKS) BOTTLE TB AURAMINE M 250ML; SYSTEM, BLOOD CULTURING Back to Search Results
Model Number 212514
Medical Device Problem Code Contamination of Device Ingredient or Reagent (2901)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 08/31/2021
Type of Reportable Event Malfunction
Event or Problem Description
It was reported that the bottle tb auramine m 250ml experienced biological contamination.The following information was provided by the initial reporter: customer reported sediments/precipitates in their bottle of tb auramine m stain from lot 0288107, exp: 2021-10-31 (cat# 212514).They are using the tb fluorescent stain kit m for the morse coloration.She didn¿t provide the stain kit lot number.
 
Additional Manufacturer Narrative
A device evaluation is anticipated, but has not yet begun.Upon completion of the investigation, a supplemental report will be filed.
 
Additional Manufacturer Narrative
The following fields were updated due to additional information: d10: device available for eval yes.D10: returned to manufacturer on: 2021-09-20.H6: investigation summary the following summary is in response against material 212514, and lot 0288107 for precipitate defects.Components are mixed and dispensed into the appropriate containers.After qc testing product is released and transported to the distribution center.The complaint investigation included a review of the batch history record tb auramine m.The batch history record review indicated no discrepancies.All release testing was satisfactory.Satisfactory appearance per the bd coa is ¿yellow suspension¿.By definition a suspension is ¿a mixture in which particles are dispersed throughout the bulk of the fluid¿.It is also defined as ¿a mixture in which all particles of a substance are dispersed throughout a gas or liquid.If a suspension is left undisturbed, the particles are likely to settle to the bottom.The particles in a suspension are larger than those in either a colloid or a solution¿.Complaint trends were reviewed for a period covering 12 months.During that time there have been no confirmed complaints for the defect in question for this product.The return received on 09/20/21.The return bottle was previously opened and almost empty.The return and retention samples from the complaint batch were evaluated along with a control batch of tb auramine m.There was a large amount of particulate visible in the return and retention samples as well as the control.Staining was completed per instructions in the product insert.Slides of positive (m.Tuberculosis atcc 25177) and negative (b.Subtilis atcc 6533) controls were evaluated and gave satisfactory staining results with the return, retention and control batches.The return and retention samples were comparable to the control.The presence of the particles is not considered a product defect for tb auramine, as they are expected to be present within the suspension, and allowable per claims on this product.Consequently, this complaint cannot be confirmed.H3 other text : see h10.
 
Event or Problem Description
It was reported that the bottle tb auramine m 250ml experienced biological contamination.The following information was provided by the initial reporter: customer reported sediments/precipitates in their bottle of tb auramine m stain from lot 0288107, exp: 2021-10-31 (cat# 212514).They are using the tb fluorescent stain kit m for the morse coloration.She didn¿t provide the stain kit lot number.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BOTTLE TB AURAMINE M 250ML
Common Device Name
SYSTEM, BLOOD CULTURING
Manufacturer (Section D)
BECTON, DICKINSON & CO. (SPARKS)
7 loveton circle
sparks MD 21152
Manufacturer (Section G)
BECTON, DICKINSON & CO. (SPARKS)
7 loveton circle
sparks MD 21152
Manufacturer Contact
katie swenson
9450 south state street
sandy, UT 84070
8015296192
MDR Report Key12558067
Report Number1119779-2021-01599
Device Sequence Number11838876
Product Code KJK
UDI-Device Identifier00382902125143
UDI-Public00382902125143
Combination Product (Y/N)N
Initial Reporter CountryCA
PMA/510(K) Number
NA
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Other,Foreign,User Facility
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 11/08/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Other
Device Expiration Date10/31/2021
Device Model Number212514
Device Catalogue Number212514
Device Lot Number0288107
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer09/20/2021
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 09/03/2021
Supplement Date Received by Manufacturer11/08/2021
Initial Report FDA Received Date09/30/2021
Supplement Report FDA Received Date11/19/2021
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured10/14/2020
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient SexUnknown
-
-